Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Ahrén

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Current Diabetes Reports|September 17, 2003
Gut peptides and type 2 diabetes mellitus treatmentBo Ahrén
Journal of Diabetes Investigation|May 19, 2022
Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in miceBo Ahrén
Experimental Cell Research|January 18, 2011
GLP-1 for type 2 diabetesBo Ahrén
Lakartidningen|January 25, 2008
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic]Bo Ahrén
Current Diabetes Reports|January 5, 2008
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitorsBo Ahrén
Vascular Health and Risk Management|June 20, 2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metforminBo Ahrén
Biomedicines|February 25, 2023
Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female MiceBo Ahrén
Lakartidningen|May 13, 2003
[Reclaim the clinical research--proposal to an action plan]Bo Ahrén
Expert Opinion on Emerging Drugs|December 3, 2008
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetesBo Ahrén
Diabetes Care|March 1, 2007
Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjectsBo Ahrén
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Current Diabetes Reports|September 17, 2003
Gut peptides and type 2 diabetes mellitus treatmentBo Ahrén
Journal of Diabetes Investigation|May 19, 2022
Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in miceBo Ahrén
Experimental Cell Research|January 18, 2011
GLP-1 for type 2 diabetesBo Ahrén
Lakartidningen|January 25, 2008
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic]Bo Ahrén
Current Diabetes Reports|January 5, 2008
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitorsBo Ahrén
Vascular Health and Risk Management|June 20, 2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metforminBo Ahrén
Biomedicines|February 25, 2023
Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female MiceBo Ahrén
Lakartidningen|May 13, 2003
[Reclaim the clinical research--proposal to an action plan]Bo Ahrén
Expert Opinion on Emerging Drugs|December 3, 2008
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetesBo Ahrén
Diabetes Care|March 1, 2007
Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjectsBo Ahrén
Pageof 25